Please ensure Javascript is enabled for purposes of website accessibility

Why Krystal Biotech Stock Is Retreating Today

By George Budwell – Dec 1, 2021 at 1:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A public offering is weighing on the biotech's shares today.

What happened

Shares of the gene therapy specialist Krystal Biotech (KRYS -2.94%) are down by 13.6% as of 1:38 p.m ET Wednesday afternoon. The biotech's shares are sinking today in response to a $200 million public offering.

More specifically, Krystal announced yesterday that it plans an offering of 2,666,667 shares of its common stock at $75 per share. This sizable capital raise follows in the wake of the company's late-stage trial success for its redosable gene therapy Vyjuvek as a treatment for the rare skin condition known as dystrophic epidermolysis bullosa (aka dystrophic EB). 

A white U-turn sign against a blue background.

Image source: Getty Images.

So what

Last Monday, Krystal's shares more than doubled in value on the back of this pivotal trial success for dystrophic EB. This massive uptick isn't surprising given that the company expects to file for Vyjuvek's approval for this rare condition in both the EU and U.S. sometime next year. What's important to understand is that Krystal may have a blockbuster product on its hands, depending on the therapy's price point. And if true, this $200 million capital raise will turn out to be a drop in the bucket compared to Vyjuvek's revenue stream. 

Now what

Is Krystal's stock a buy on this double-digit pullback? Wall Street thinks this small-cap biotech stock still has an 80% upside potential remaining, even after Monday's enormous rally. While investors should always take analyst price targets with a huge grain of salt, there may be something to this stellar forecast. Vyjuvek, after all, is a truly unique therapy that would meet the needs of an underserved patient population. In short, aggressive investors may want to consider scooping up some shares on this dip. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.